Idelalisib-Induced Pneumonitis in Chronic Lymphocytic Leukemia

Idelalisib-Induced Pneumonitis in Chronic Lymphocytic Leukemia

Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, effectively treats relapsed chronic lymphocytic leukemia (CLL). While this targeted approach offers a therapeutic edge, particularly in B-cell malignancies, it is associated with complications such as pneumonitis. This report details i...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Curēus (Palo Alto, CA) CA), 2024-05, Vol.16 (5), p.e59541
Hauptverfasser: Ravi, Sasikanth N, Choi, Irene W, Ngapgue, Eva K, Stroiney, Amanda G, Miranda, Clive J
Format: Artikel
Sprache:eng
Schlagworte:
Drug dosages
Dyspnea
Infections
Internal medicine
Leukemia
Medicine
Patients
Steroids
Toxicity
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Idelalisib, a phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, effectively treats relapsed chronic lymphocytic leukemia (CLL). While this targeted approach offers a therapeutic edge, particularly in B-cell malignancies, it is associated with complications such as pneumonitis. This report details idelalisib-induced pneumonitis, highlighting the importance of early diagnosis and tailored treatment in achieving a favorable patient outcome.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.59541